![](https://webarchive.library.unt.edu/eot2008/20081004021316im_/http://www.fda.gov/cder/templates/graphics/dot_clear.gif) |
Ezetimibe/Simvastatin (marketed as Vytorin) Information
- Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia):
- Information for Healthcare Professionals: The FDA notifies the public of the risk of a rare condition of muscle injury called rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. (8/8/2008)
- Consumer Information
Back
to Top Back to Drug Index
PDF requires the free Adobe Acrobat Reader
Date created: August 21, 2008
|
![](https://webarchive.library.unt.edu/eot2008/20081004021316im_/http://www.fda.gov/cder/templates/graphics/dot_clear.gif) |